Group One Trading
CRNX icon

Group One Trading’s Crinetics Pharmaceuticals CRNX Stock Holding History

Group One Trading’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.2K Sell
500
-11,400
-96% -$509K ﹤0.01% 6026
2025
Q4 		$554K Sell
11,900
-22,300
-65% -$993K ﹤0.01% 3403
2025
Q3 		$1.42M Sell
34,200
-12,500
-27% -$400K ﹤0.01% 2664
2025
Q2 		$1.34M Buy
46,700
+45,700
+4,570% +$1.41M ﹤0.01% 2492
2025
Q1 		$33.5K Buy
1,000
+700
+233% +$26.1K ﹤0.01% 5471
2024
Q4 		$15.3K Sell
300
-1,000
-77% -$55.9K ﹤0.01% 5864
2024
Q3 		$66.4K Buy
1,300
+300
+30% +$15.5K ﹤0.01% 4460
2024
Q2 		$44.8K Sell
1,000
-1,600
-62% -$73.9K ﹤0.01% 4601
2024
Q1 		$122K Sell
2,600
-23,800
-90% -$931K ﹤0.01% 3986
2023
Q4 		$939K Buy
26,400
+15,000
+132% +$460K ﹤0.01% 2505
2023
Q3 		$339K Buy
+11,400
New +$235K ﹤0.01% 3315

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Group One Trading's CRNX Position: Q3 2025 in Review

Group One Trading sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2025, closing a stake of 2,796 shares — an estimated $89.4K sold.

Group One Trading first reported a position in CRNX in Q4 2021 and held it in 7 quarters. The position peaked at $245K in Q3 2023. 225 funds tracked by Wall St. Rank hold CRNX as of Q3 2025.

  • Group One Trading reported no remaining Crinetics Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Group One Trading sold 2,796 Crinetics Pharmaceuticals shares in Q3 2025, an estimated $89.4K.
  • Group One Trading first reported a position in Crinetics Pharmaceuticals in Q4 2021 and held it in 7 quarters.
  • Group One Trading's Crinetics Pharmaceuticals position peaked at $245K in Q3 2023.
  • 225 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2025.

Based on Group One Trading's 13F filing for Q3 2025, filed 12 Nov 2025.